1. |
Guidelines for the management of hepatitis C |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Psychotropic drug use in Italy: impact of policy changes |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Switch to levofloxacin for cost savings in CAP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Omalizumab corticosteroid-sparing in paediatric allergic asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Biologicals for psoriasis showing promise in long-term treatment |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 7-8
Ed Susman,
Preview
|
|
摘要:
Researchers at the Summer Scientific Meeting of the American Academy of Dermatology [Anaheim, US; July 2001] reported the continued clinical promise of two new biological agents that interfere with the molecular cascade of events underlying plaque psoriasis. These new studies show that the human LFA-3/immunoglobulinG-1 fusion protein alefacept, and the anti-CD11a monoclonal antibody efalizumab ['Xanelim'], appear to be effective in reducing the severity of the disease over extended periods of use. In one study, researchers reported success in the retreatment of patients with a second course of alefacept, a critical accomplishment given that the drug is being developed to be delivered by intermittent therapy.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Pegylated liposomal doxorubicin promising in ovarian cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Success with salvage therapy in HIV infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1304,
2001,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
A large number of patients with HIV infection have virus which has developed resistance to antiretrovirals, particularly protease inhibitors, resulting in treatment failure. Ritonavir has been increasingly used in combination with other protease inhibitors, including indinavir and lopinavir, because of its ability to improve plasma drug concentrations and prolong the half-life of other protease inhibitors. At the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment [Buenos Aires, Argentina; July 2001], two studies reported the use of ritonavir as part of salvage therapy in patients with HIV infection. In the first study, patients who had experienced virological failure while receiving indinavir-based therapy achieved undetectable viral loads when ritonavir was added to their regimen. In the second study, response to multiple drug rescue therapy in heavily-pretreated patients was enhanced when lopinavir/ritonavir was part of the regimen. A third interesting study looked at the efficacy of PEG interferon (IFN)-α-2b in patients with HIV infection failing highly active antiretroviral therapy (HAART), and found that viral loads were decreased after 4 weeks, suggesting that this cytokine may have a therapeutic role in the treatment of such patients.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|